Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CM-101 in healthy male subjects
NCT06037577Phase 1Completed
- Sponsor
- Chemomab Therapeutics
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) and systemic sclerosis (SSc) comparing CM-101 5 mg/kg with Placebo (2 arms). Primary endpoints: Incidence and characteristics of adverse events (AEs) at 10 weeks, Maximum CM-101 plasma concentration at 10 weeks and 4 more. Started Mar 2019; status: completed.
02
Drugs
nebokitug
03
Conditions
Nonalcoholic steatohepatitis (NASH)Primary Sclerosing Cholangitis (PSC)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06037577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037577.